secwatch.observer — SEC 8-K summary
======================================

Issuer:     Lipocine Inc. (LPCN)
CIK:        0001535955
Form:       8-K
Filed at:   2022-04-11T23:59:59+00:00
Accession:  0001493152-22-009538
Event type: leadership
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Lipocine appoints Jill M. Jene and Spyros Papapetropoulos to board of directors
-------------------------------------------------------------------------------

- Board expanded to six members; Dr. Jene and Dr. Papapetropoulos appointed effective April 11, 2022.
- Both are independent directors under Nasdaq rules; Dr. Jene will serve on Audit Committee, Dr. Papapetropoulos on Compensation Committee.
- Each new director receives an initial option grant for 10,000 shares and $35,000 annual retainer plus $5,000 for committee service.
- Dr. Jene brings over 20 years of biopharma strategy and deal-making; Dr. Papapetropoulos has neuroscience expertise and experience as CMO at multiple firms.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1535955/000149315222009538/0001493152-22-009538-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1535955/000149315222009538/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-22-009538

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer